Total Voting Rights

RNS Number : 0240P

Alliance Pharma PLC

04 February 2019

 

For immediate release

4 February 2019

 

 

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Total Voting Rights

Alliance Pharma plc (AIM: APH), the specialty pharmaceutical group, makes the following notification in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1.

As at 31 January 2019 the Company's issued share capital consists of 518,230,255 Ordinary Shares of 1p each.

The total number of voting rights in the Company is 518,230,255 and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information:

Alliance Pharma plc                                                                                          + 44 (0) 1249 466966

Peter Butterfield, Chief Executive Officer

Andrew Franklin, Chief Financial Officer

www.alliancepharma.co.uk 

Buchanan                                                                                                            + 44 (0) 20 7466 5000

Mark Court / Sophie Wills / Hannah Ratcliff

Numis Securities Limited                                                                                  + 44 (0) 20 7260 1000

Nominated Adviser: Michael Meade / Freddie Barnfield

Corporate Broking: James Black

Investec Bank plc                                                                                               [phone]

Corporate Finance: Daniel Adams / Ed Thomas

Corporate Broking: Patrick Robb / Rob Baker

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

 

END

 

 

TVRUGURWPUPBGAC